Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognostic significance of 1q21 gain/amplification and co-existing cytogenetic abnormalities in Chinese patients with newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYi LiMZMing ZhaoHXHaowen Xiao

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 1q21 gain significantly worsens progression-free survival in Chinese patients, suggesting improved risk stratification is needed.

Key Points

  • This research evaluates the prognostic significance of 1q21 gain and cytogenetic abnormalities in newly diagnosed multiple myeloma patients.
  • Retrospective analysis of 658 patients treated from July 2013 to June 2022.
  • Patients stratified based on interphase FISH results into groups: no 1q21+, isolated 1q21+, 1q21+ with NHRCA, and 1q21+ with HRCA.
  • Treatment response assessed using IMWG criteria.
  • Median progression-free survival was 37.2 months across the cohort.
  • Patients with isolated 1q21+ had a median progression-free survival of 33.7 months.
  • Patients with both 1q21+ and HRCA had significantly worse survival outcomes (OS < 40 months).

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0bahttps://doi.org/10.1182/blood-2025-2242
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China2024 · 4 citations
  2. 2Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience2026
  3. 3Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients2024 · 1 citations
  4. 4Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens2026 · 1 citations
  5. 5P21 | THE LONG TERM PROGNOSTIC IMPACT OF CHROMOSOME 1 ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS2026